JP2017505755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505755A5 JP2017505755A5 JP2016536543A JP2016536543A JP2017505755A5 JP 2017505755 A5 JP2017505755 A5 JP 2017505755A5 JP 2016536543 A JP2016536543 A JP 2016536543A JP 2016536543 A JP2016536543 A JP 2016536543A JP 2017505755 A5 JP2017505755 A5 JP 2017505755A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912156P | 2013-12-05 | 2013-12-05 | |
| US61/912,156 | 2013-12-05 | ||
| PCT/IL2014/051058 WO2015083167A1 (en) | 2013-12-05 | 2014-12-04 | Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505755A JP2017505755A (ja) | 2017-02-23 |
| JP2017505755A5 true JP2017505755A5 (enExample) | 2017-12-14 |
| JP6609556B2 JP6609556B2 (ja) | 2019-11-20 |
Family
ID=52292983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536543A Active JP6609556B2 (ja) | 2013-12-05 | 2014-12-04 | 転移がんの治療および予防のための医薬組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9878015B2 (enExample) |
| EP (1) | EP3076988B1 (enExample) |
| JP (1) | JP6609556B2 (enExample) |
| KR (1) | KR102384795B1 (enExample) |
| CN (1) | CN105939724B (enExample) |
| AU (1) | AU2014358671B2 (enExample) |
| CA (1) | CA2931023C (enExample) |
| DK (1) | DK3076988T3 (enExample) |
| ES (1) | ES2742856T3 (enExample) |
| IL (1) | IL245998B (enExample) |
| WO (1) | WO2015083167A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102667913B1 (ko) * | 2016-02-04 | 2024-05-21 | 이뮨 시스템 키 엘티디. | 암의 치료를 위한 암 요법 및 병용 요법에서 예측 툴로서의 소포체 스트레스 |
| EP4534546A1 (en) * | 2022-05-27 | 2025-04-09 | Zincure Corp. | Novel peptide and use thereof |
| EP4688805A1 (en) * | 2023-05-03 | 2026-02-11 | Immune System Key Ltd. | Cyclic d-peptides, derivatives, compositions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101310511B1 (ko) * | 2004-10-25 | 2013-09-25 | 임뮨 시스템 키 리미티드 | 흉선-특이성 단백질 |
| WO2007091240A2 (en) * | 2006-02-06 | 2007-08-16 | Immune System Key Ltd. | Treatment of immunological diseases |
| WO2007122622A1 (en) * | 2006-04-24 | 2007-11-01 | Immune System Key Ltd. | Method of treatment of a disease |
| WO2008075349A1 (en) | 2006-12-18 | 2008-06-26 | Immune System Key Ltd. | Therapeutic methods using a thymus peptide |
-
2014
- 2014-12-04 DK DK14824545.9T patent/DK3076988T3/da active
- 2014-12-04 CA CA2931023A patent/CA2931023C/en active Active
- 2014-12-04 CN CN201480074295.5A patent/CN105939724B/zh active Active
- 2014-12-04 KR KR1020167017549A patent/KR102384795B1/ko active Active
- 2014-12-04 EP EP14824545.9A patent/EP3076988B1/en active Active
- 2014-12-04 ES ES14824545T patent/ES2742856T3/es active Active
- 2014-12-04 US US15/102,094 patent/US9878015B2/en active Active
- 2014-12-04 WO PCT/IL2014/051058 patent/WO2015083167A1/en not_active Ceased
- 2014-12-04 JP JP2016536543A patent/JP6609556B2/ja active Active
- 2014-12-04 AU AU2014358671A patent/AU2014358671B2/en active Active
-
2016
- 2016-06-02 IL IL245998A patent/IL245998B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhatt et al. | Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status | |
| JP2015505843A5 (enExample) | ||
| JP2016538344A5 (enExample) | ||
| RU2017126601A (ru) | Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras | |
| JP2016535009A5 (enExample) | ||
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| JP2016506413A5 (enExample) | ||
| JP2009538932A5 (enExample) | ||
| JP2016531927A5 (enExample) | ||
| JP2014533247A5 (enExample) | ||
| NZ726365A (en) | Combinations for treating cancers | |
| JP2016520057A5 (enExample) | ||
| JP2016519069A5 (enExample) | ||
| JP2017505755A5 (enExample) | ||
| Panahizadeh et al. | Cytotoxicity of curcumin against CD44±prostate cancer cells: Roles of miR-383 and miR-708 | |
| JP2014510699A5 (enExample) | ||
| MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
| Zhang et al. | MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment | |
| Bowling et al. | Emerging developments in ETS-positive prostate cancer therapy | |
| Wang et al. | Melittin treatment suppressed malignant NSCLC progression through enhancing CTSB-mediated hyperautophagy | |
| RU2018107330A (ru) | Индуктор иммунитета | |
| Ooi et al. | RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update | |
| EP4461371A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| JP2016531120A5 (enExample) | ||
| Kim et al. | PIK3CA mutations in hepatocellular carcinoma in Korea |